Meiji Yasuda Asset Management Co Ltd. cut its stake in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 77.0% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 2,788 shares of the medical research company's stock after selling 9,354 shares during the period. Meiji Yasuda Asset Management Co Ltd.'s holdings in IQVIA were worth $548,000 as of its most recent SEC filing.
A number of other institutional investors have also recently bought and sold shares of the stock. Smith Group Asset Management LLC acquired a new position in shares of IQVIA in the 4th quarter valued at about $1,616,000. Nordea Investment Management AB grew its stake in IQVIA by 47.4% during the fourth quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company's stock worth $277,908,000 after buying an additional 452,029 shares during the period. Hickory Asset Management Inc. acquired a new stake in shares of IQVIA in the fourth quarter worth $941,000. Fifth Third Bancorp raised its stake in shares of IQVIA by 13.0% in the 4th quarter. Fifth Third Bancorp now owns 13,179 shares of the medical research company's stock valued at $2,590,000 after acquiring an additional 1,521 shares during the period. Finally, Graphene Investments SAS boosted its position in IQVIA by 22.0% during the 4th quarter. Graphene Investments SAS now owns 15,000 shares of the medical research company's stock worth $2,948,000 after purchasing an additional 2,700 shares during the period. 89.62% of the stock is currently owned by hedge funds and other institutional investors.
IQVIA Stock Performance
NYSE IQV traded down $1.86 during trading hours on Tuesday, hitting $174.45. The company had a trading volume of 181,194 shares, compared to its average volume of 1,298,673. IQVIA Holdings Inc. has a fifty-two week low of $169.37 and a fifty-two week high of $253.84. The firm has a market cap of $30.76 billion, a P/E ratio of 23.26, a price-to-earnings-growth ratio of 1.99 and a beta of 1.50. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.12. The business has a fifty day simple moving average of $192.73 and a 200-day simple moving average of $205.61.
IQVIA (NYSE:IQV - Get Free Report) last issued its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. Equities analysts predict that IQVIA Holdings Inc. will post 10.84 EPS for the current year.
Wall Street Analyst Weigh In
Several research analysts have commented on IQV shares. JPMorgan Chase & Co. cut their price objective on IQVIA from $240.00 to $232.00 and set an "overweight" rating on the stock in a research report on Tuesday, February 18th. Truist Financial restated a "buy" rating and issued a $263.00 price target (up previously from $261.00) on shares of IQVIA in a report on Monday, February 10th. BTIG Research cut shares of IQVIA from a "buy" rating to a "neutral" rating in a research report on Monday, February 3rd. Robert W. Baird dropped their price target on shares of IQVIA from $212.00 to $210.00 and set a "neutral" rating on the stock in a research note on Tuesday, January 21st. Finally, William Blair reaffirmed an "outperform" rating on shares of IQVIA in a research report on Wednesday, December 11th. Five research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $249.05.
View Our Latest Analysis on IQVIA
About IQVIA
(
Free Report)
IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
Further Reading
Before you consider IQVIA, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IQVIA wasn't on the list.
While IQVIA currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering when you'll finally be able to invest in SpaceX, Starlink, or X.AI? Enter your email address to learn when Elon Musk will let these companies finally IPO.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
